Sun Pharma Inks Non-Exclusive License Agreement With Takeda To Introduce Vonoprazan Tablets In India

New Delhi: Sun Pharmaceutical Industries on Friday said it has inked a licensing pact with Takeda Pharmaceutical Company to commercialise a novel gastrointestinal drug in India.

The company has entered into a non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan tablets in strengths of 10 and 20 mg in India, the Mumbai-based drug major said in a statement.

Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders.

“Sun Pharma is a leader in gastroenterology and we are excited to introduce Vonoprazan in India under non-exclusive patent license from Takeda,” Sun Pharma CEO – India Business Kirti Ganorkar said.

The partnership demonstrates the company’s commitment to gastrointestinal health by providing patients and healthcare practitioners with a novel treatment option to manage reflux esophagitis and other acid peptic disorders, he added.

Gastroesophageal Reflux Disease (GERD) is common in India.

In November 2023, Vonoprazan was approved by the US FDA for healing and maintenance of all grades of Erosive esophagitis and providing relief from heartburn associated with Erosive esophagitis, and in combination with amoxicillin and clarithromycin or amoxicillin alone for the treatment of Helicobacter pylori (H. pylori) infection in adults.

Vonoprazan was discovered and developed by Takeda.

The drug is approved in India for treatment of adults with reflux esophagitis and other acid peptic disorders.

Related Posts

  • Pharma
  • July 13, 2024
  • 117 views
Telangana DCA Seizes Overpriced Anti-Cancer Medicine In Karimnagar

Hyderabad: Drugs Control Administration officials seized ‘Dacazee 500 Injection’ (Dacarbazine Injection IP 500 mg), during the raids carried out on 11th and 12th July, 2024, at a medical shop located in…

  • Pharma
  • July 13, 2024
  • 84 views
Drug Price Regulation Leads To Decline In Availability Of Essential Medicines, Study Finds

Kolkata: The Drug Price Control Order (DPCO) 2013, India’s key drug regulation aimed at making essential medicines more affordable, has inadvertently led to a decline in the availability of these…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Telangana DCA Seizes Overpriced Anti-Cancer Medicine In Karimnagar

Telangana DCA Seizes Overpriced Anti-Cancer Medicine In Karimnagar

Drug Price Regulation Leads To Decline In Availability Of Essential Medicines, Study Finds

Drug Price Regulation Leads To Decline In Availability Of Essential Medicines, Study Finds

EMA Warns Of Anaphylactic Reactions To MS Drug

EMA Warns Of Anaphylactic Reactions To MS Drug

14 Barred Patanjali Products Sold Across Counter At Dedicated Stores

14 Barred Patanjali Products Sold Across Counter At Dedicated Stores

Mumbai: FDA Conducts Raids At Three Different Locations In Vasai, Seized Ayurvedic Drugs Worth Rs 1.41 Crore

Mumbai: FDA Conducts Raids At Three Different Locations In Vasai, Seized Ayurvedic Drugs Worth Rs 1.41 Crore

Telangana DCA Raids 2 Places, Seizes Illegally Stocked And Overpriced Medicines

Telangana DCA Raids 2 Places, Seizes Illegally Stocked And Overpriced Medicines